About InVitae (NYSE:NVTA)
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Medical laboratories
Trailing P/E Ratio-3.06
Forward P/E Ratio-3.76
Sales & Book Value
Annual Sales$68.22 million
Price / Sales8.00
Price / CashN/A
Book Value$2.30 per share
Price / Book3.53
EPS (Most Recent Fiscal Year)($2.65)
Return on Equity-127.38%
Return on Assets-68.70%
InVitae (NYSE:NVTA) Frequently Asked Questions
What is InVitae's stock symbol?
InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were InVitae's earnings last quarter?
InVitae Corp (NYSE:NVTA) issued its quarterly earnings results on Wednesday, May, 9th. The medical research company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.05. The medical research company earned $27.67 million during the quarter, compared to analysts' expectations of $26.86 million. InVitae had a negative return on equity of 127.38% and a negative net margin of 154.96%. InVitae's revenue for the quarter was up 167.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.64) earnings per share. View InVitae's Earnings History.
When is InVitae's next earnings date?
What price target have analysts set for NVTA?
4 Wall Street analysts have issued 1-year price objectives for InVitae's shares. Their forecasts range from $9.00 to $15.00. On average, they expect InVitae's share price to reach $11.00 in the next twelve months. View Analyst Ratings for InVitae.
Who are some of InVitae's key competitors?
Some companies that are related to InVitae include Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), CareDx (CDNA), Veracyte (VCYT), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Celcuity (CELC), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC) and OpGen (OPGN).
Who are InVitae's key executives?
InVitae's management team includes the folowing people:
- Dr. Randal W. Scott, Exec. Chairman (Age 60)
- Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 44)
- Dr. Robert L. Nussbaum, Chief Medical Officer (Age 68)
- Ms. Shelly D. Guyer, Chief Financial Officer (Age 58)
- Mr. Lee Bendekgey, Chief Operating Officer (Age 60)
When did InVitae IPO?
(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Has InVitae been receiving favorable news coverage?
Media headlines about NVTA stock have been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. InVitae earned a media sentiment score of 0.16 on Accern's scale. They also gave media coverage about the medical research company an impact score of 47.44 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are InVitae's major shareholders?
InVitae's stock is owned by a number of of retail and institutional investors. Top institutional investors include ARK INVESTMENT MANAGEMENT LLC (10.84%), WELLINGTON MANAGEMENT PORTFOLIOS (DUBLIN) PUBLIC LTD COMPANY (5.23%), BlackRock Inc. (5.15%), Redmile Group LLC (3.18%), Rock Springs Capital Management LP (2.08%) and CVI Holdings LLC (0.67%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae.
Which institutional investors are selling InVitae stock?
NVTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC and Schwab Charles Investment Management Inc.. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Katherine Stueland, Patty Dumond, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Insider Buying and Selling for InVitae.
Which institutional investors are buying InVitae stock?
NVTA stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, BlackRock Inc., Victory Capital Management Inc., Rock Springs Capital Management LP, Blair William & Co. IL, Dimensional Fund Advisors LP, Gamco Investors INC. ET AL and Teton Advisors Inc.. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse and Randal W Scott. View Insider Buying and Selling for InVitae.
How do I buy shares of InVitae?
Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is InVitae's stock price today?
One share of NVTA stock can currently be purchased for approximately $8.12.
How big of a company is InVitae?
InVitae has a market capitalization of $545.70 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. InVitae employs 594 workers across the globe.
How can I contact InVitae?
InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for InVitae (NVTA)MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.